Literature DB >> 23001043

MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1.

S Yang1, Y Li, J Gao, T Zhang, S Li, A Luo, H Chen, F Ding, X Wang, Z Liu.   

Abstract

MicroRNAs have key roles in tumor metastasis. Here, we describe the regulation and function of miR-34a and miR-34c (miR-34a/c) in breast cancer metastasis. Expression analysis verified that miR-34a/c expression is significantly decreased in metastatic breast cancer cells and human primary breast tumors with lymph node metastases. Overexpression of miR-34a/c could inhibit breast cancer cell migration and invasion in vitro and distal pulmonary metastasis in vivo. Further studies revealed that Fos-related antigen 1 (Fra-1 or Fosl1) is a downstream target of miR-34a/c as miR-34a/c bound directly to the 3'untranslated region of Fra-1, subsequently reducing both the mRNA and protein levels of Fra-1. Silencing of Fra-1 recapitulated the effects of miR-34a/c overexpression, whereas enforced expression of Fra-1 reverses the suppressive effects of miR-34a/c. Moreover, significant downregulation of miR-34a in metastatic breast cancer tissues was found to be inversely correlated with Fra-1 expression. Our results demonstrate that miR-34a/c functions as a metastasis suppressor to regulate breast cancer migration and invasion through targeting Fra-1 oncogene and suggest a therapeutic application of miR-34 in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23001043     DOI: 10.1038/onc.2012.432

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  110 in total

1.  Transcriptional control of PAX4-regulated miR-144/451 modulates metastasis by suppressing ADAMs expression.

Authors:  J Zhang; X Qin; Q Sun; H Guo; X Wu; F Xie; Q Xu; M Yan; J Liu; Z Han; W Chen
Journal:  Oncogene       Date:  2014-08-25       Impact factor: 9.867

Review 2.  MicroRNAs and other non-coding RNAs as targets for anticancer drug development.

Authors:  Hui Ling; Muller Fabbri; George A Calin
Journal:  Nat Rev Drug Discov       Date:  2013-11       Impact factor: 84.694

Review 3.  Expression and function of FRA1 protein in tumors.

Authors:  Xiaoyan Jiang; Hui Xie; Yingyu Dou; Jing Yuan; Da Zeng; Songshu Xiao
Journal:  Mol Biol Rep       Date:  2019-10-14       Impact factor: 2.316

4.  Proteotranscriptomic Profiling of 231-BR Breast Cancer Cells: Identification of Potential Biomarkers and Therapeutic Targets for Brain Metastasis.

Authors:  Matthew D Dun; Robert J Chalkley; Sam Faulkner; Sheridan Keene; Kelly A Avery-Kiejda; Rodney J Scott; Lasse G Falkenby; Murray J Cairns; Martin R Larsen; Ralph A Bradshaw; Hubert Hondermarck
Journal:  Mol Cell Proteomics       Date:  2015-06-03       Impact factor: 5.911

Review 5.  Kallistatin suppresses cancer development by multi-factorial actions.

Authors:  Julie Chao; Pengfei Li; Lee Chao
Journal:  Crit Rev Oncol Hematol       Date:  2017-03-14       Impact factor: 6.312

Review 6.  Regulation of microRNAs in cancer metastasis.

Authors:  Juliette M C Bouyssou; Salomon Manier; Daisy Huynh; Samar Issa; Aldo M Roccaro; Irene M Ghobrial
Journal:  Biochim Biophys Acta       Date:  2014-02-22

7.  MicroRNA-548j functions as a metastasis promoter in human breast cancer by targeting Tensin1.

Authors:  Yun Zhan; Xiaoshuan Liang; Lin Li; Baona Wang; Fang Ding; Yi Li; Xiang Wang; Qimin Zhan; Zhihua Liu
Journal:  Mol Oncol       Date:  2016-02-23       Impact factor: 6.603

8.  MiR-34c inhibits osteosarcoma metastasis and chemoresistance.

Authors:  Meng Xu; Hua Jin; Cheng-Xiong Xu; Wen-Zhi Bi; Yan Wang
Journal:  Med Oncol       Date:  2014-05-07       Impact factor: 3.064

Review 9.  The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas.

Authors:  Brian D Adams; Christine Parsons; Frank J Slack
Journal:  Expert Opin Ther Targets       Date:  2015-12-11       Impact factor: 6.902

10.  miR-34c-3p functions as a tumour suppressor by inhibiting eIF4E expression in non-small cell lung cancer.

Authors:  Fang Liu; Xuefeng Wang; Jiebing Li; Kuo Gu; Liyan Lv; Shuai Zhang; Dehai Che; Jingyan Cao; Shi Jin; Yan Yu
Journal:  Cell Prolif       Date:  2015-08-06       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.